Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
afimoxifene
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Besins Healthcare
Drug class:
Selective estrogen receptor modulator
Related drugs:
‹
toremifene (4)
lasofoxifene (3)
Z-endoxifen hydrochloride (2)
Z-endoxifen (1)
acolbifene (0)
LY353381 (0)
ormeloxifene (0)
raloxifene hydrochloride (0)
toremifene (4)
lasofoxifene (3)
Z-endoxifen hydrochloride (2)
Z-endoxifen (1)
acolbifene (0)
LY353381 (0)
ormeloxifene (0)
raloxifene hydrochloride (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (NCT02993159)
Phase 2b
Northwestern University
Northwestern University
Recruiting
Phase 2b
Northwestern University
Recruiting
Last update posted :
12/21/2020
Initiation :
05/31/2017
Primary completion :
07/15/2022
Completion :
07/15/2023
ER • IGF1 • CD68
|
ER positive
|
afimoxifene • Soltamox (tamoxifen citrate)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login